2nd Line Relapsed or Metastatic Mucosal HNSCC not NPC

Treatment

No Injectable Lesions

No Prior Chemo in R/M Setting

ENT0100
- Phase I Multicenter Open Label
  First-in-Human ABBV-CLS-579 Alone and in Combination in Locally Advanced or Metastatic Tumors
  PI: Colevas Sponsor: AbbVie Inc.

Max 2 Prior Therapies

ENT0088
- Phase II Magnolimab Combination Therapy in Head and Neck Squamous Cell Carcinoma
  Safety Run-in 2 / Phase 2 Cohort 3
  PI: Colevas Sponsor: Gilead Sciences, Inc.

Max 4 Prior Therapies in R/M Setting

ENT0105
- Phase II Study of SRF114 in Patients With Advanced Solid Tumors
  PI: Colevas Sponsor: Surface Oncology, Inc.

ENT0108
- Phase II Open-Label Study of Ozuritamab Vedotin (BA3021) in PD-1/L1 Failure Patients w/ Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
  PI: Colevas Sponsor: BioAtla, Inc.

Injectable Lesions

ENT0064
- Phase Ib Adj/PNP-FlaraAMP w/ Co-Admin of Fludarabine Phosphosphate in Recurrent Local Head and Neck Cancer
  PI: Colevas Sponsor: PNP Therapeutics

ECOG-ACRIN- Ea3202
- Phase I/III Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent / Metastatic Head & Neck Cancers
  PI: Khan Sponsor: ECOG-ACRIN

KEY
- Pending
- Open for Enrollment
- Optional Path
- Link
- Trial Posting
- Extension Study
- Immunotherapy
- Enrollment on Hold